Neurosense Therapeutics 在二期B阶段ALS研究中达到首要终点,显著降低ALS标志性病理蛋白Tdp-43

美股速递
Jun 29

NeuroSense Therapeutics Ltd 在其针对肌萎缩侧索硬化症(ALS)的二期B阶段临床试验中,成功达到了首要研究终点。数据显示,治疗显著降低了Tdp-43蛋白的水平,而该蛋白是定义ALS病理特征的关键标志物,且这一降低具有统计学意义。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10